Reduced expression of PDLIM4 gene correlates with good prognosis in acute myeloid leukemia.
10.7534/j.issn.1009-2137.2013.05.005
- Author:
Yun LI
1
;
Jun QIAN
;
Jiang LIN
;
Wei QIAN
;
Jing YANG
;
Hai-Yan CHAI
;
Cui-Zhu WANG
;
Zhao-Qun DENG
;
Dong-Ming YAO
;
Qin CHEN
;
Ji-Chun MA
Author Information
1. Department of Hematology, Central Laboratory, Jiangsu University People's Hospital, Zhenjiang 212002, Jiangsu Province, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Biomarkers, Tumor;
metabolism;
Case-Control Studies;
DNA-Binding Proteins;
genetics;
metabolism;
Female;
Humans;
LIM Domain Proteins;
genetics;
metabolism;
Leukemia, Myeloid, Acute;
diagnosis;
genetics;
metabolism;
Male;
Middle Aged;
Prognosis;
Young Adult
- From:
Journal of Experimental Hematology
2013;21(5):1111-1115
- CountryChina
- Language:English
-
Abstract:
This study was aimed to investigate the expression pattern of gene PDLIM4 (PDZ and LIM domain 4) and analyze its clinical correlation with the patients suffered from acute myeloid leukemia (AML). The expression pattern of PDLIM4 in AML was detected by using EvaGreen real-time quantitative PCR (RQ-PCR). The results showed that the PDLIM4 transcript significantly decreased in 94 AML patients, compared with 21 controls (P < 0.01). The decrease of PDLIM4 transcript was found in 42 (45%) AML patients. PDLIM4 low-expression occurred among the subtypes of M1/M2/M3 more frequently than that in M4/M5/M6 (56% vs 20%, P < 0.01). AML patients with PDLIM4 low-expression had an overall survival (OS) higher than that in AML patients without PDLIM4 low-expression (P < 0.05). Analysis with receiver operating characteristic curve (ROC) displayed that PDLIM4 expression possesses the diagnostic value to differentiate AML from controls, with ROC curve area of 0.865 (95% CI: 0.801-0.930). It is concluded that reduced PDLIM4 expression is a common and favorable event for the good prognosis in AML, and can be used as a potential diagnostic biomarker of cancer.
